Maralixibat for Intrahepatic Cholestasis of Pregnancy

Phase 2 Not yet recruiting 28 enrolled Imperial College London Mirum Pharmaceuticals, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

An open label phase 2a/b trial of maralixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability

Timeline

Start: 2026-04-01
Primary completion: 2028-03-31
Completion: 2028-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Maralixibat	Small molecule	—	Oral

Maralixibat for Intrahepatic Cholestasis of Pregnancy

Summary

Timeline

Drugs

Indications